Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 15/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668449 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BDHFR | |
| SCHEMBL29051638 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL30514650 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1 | |
| SCHEMBL30162646 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1ADORA3DHFRKDM4E | |
| SCHEMBL13322063 | 0.73 | ADORA2A (0.61) | ADORA2AADORA1ADORA3ADORA2BDHFR | |
| SCHEMBL4044550 | 0.72 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2BDHFR | |
| SCHEMBL1553903 | 0.71 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BDHFRKDM4E | |
| SCHEMBL3587423 | 0.71 | ADORA2A (0.55) | ADORA2AADORA1DHFRALDH1A1HSD17B10 | |
| SCHEMBL2910353 | 0.71 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BDHFRKDM4E | |
| SCHEMBL6948083 | 0.71 | ADORA2A (0.63) | ADORA2AADORA1ADORA3ADORA2BDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | claimed |
| US-7087754-B2 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-08 | — | — | US | claimed |
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2006-05-25 | — | — | US | claimed |
| CN-116589464-A | Pyrimidine ring compound, preparation method and application thereof | 上海科技大学 | 2023-08-15 | — | — | CN | disclosed |
| WO-2019086074-A1 | 4-(FURAN-2-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-AMINE DERIVATIVE AND USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2019-05-09 | — | — | WO | disclosed |
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1349552-B1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-7087754-B2 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-20040116447-A1 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | CHRNA6, CHRNA5, CNR1 | ADORA2A 6/4885ADORA1 15/4885ADORA3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.